Assessment of the Pharmacokinetic Profile of Tacrolimus Medications and Their Relation to Effectiveness and Safety in Liver Transplant Patients

Liver Failure Clinical Trial

— LTA  

Official title:

Assessment of the Pharmacokinetic Profile of Tacrolimus Medications in Liver Transplant Patients

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05744635
• Other study ID #: LTA_2022
• Status: Recruiting
• Start date: May 10, 2023
• Est. completion date: June 1, 2026

Study information

• Verified date: June 2023
• Source: Chiesi Hungary Ltd.
• Contact: Ákos Szeredi, MD
• Phone: +36707772232
• Email: a.szeredi[@]chiesi.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The goal of this observational study is oo compare the pharmacokinetic parameters of different tacrolimus containing medications in liver transplant patients. The main question[s] it aims to answer are:

• Differences in pharmacokinetic parameters of tacrolimus containing medicinal products (TL, TDD and their ratio - C/D)

• Changes in liver function parameters compared to baseline.

• Change in the estimated glomerular filtration rate (eGFR) compared to baseline.

• To assess the possible relation of liver function parameters and eGFR to C/D (blood concentration and daily dosage)

• Incidence of acute graft rejection during the study

• Incidence of BK and cytomegalovirus (CMV) infection during the study

• To assess the intraindividual variability of the TL, TDD and the ratios of these parameters (C/D)

• To assess the patient-adherence of therapy based on the BAASIS questionnaire, and prescription filled by individual patients, based on electronic health-care record.

Participants will not have to undergo any additional clinical visits or tests except which are required in routine clinical care

Description:

The primary aim of the study is to assess tolerability of LCPT and graft function within the 24-month observational period. Other objectives include the assessment of the intraindividual variability of the TL and TDD, the incidence of BK and cytomegalovirus infections, the incidence of graft insufficiency and acute and chronic graft rejection. There are few real-life studies available on maintenance treatment regimens in liver transplant patients throughout Europe, and these only focus on the healthcare resources' consumption. There is a lack of data describing the effectiveness of different drugs and their combinations in early maintenance immunosuppression in the real-life setting. Even less data is available of ISU (immunosuppression) drugs combinations' metabolism and its relation to effectiveness and safety, measured in liver transplant patients.

Given the above considerations we planned this non-interventional study (NIS) to assess pharmacokinetic parameters of LCPT and other tacrolimus containing medications and their relation to efficacy and tolerability in hepatic allograft recipients in a real-life setting.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 110
• Est. completion date: June 1, 2026
• Est. primary completion date: March 1, 2026
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Patients = 18 years of age

2. Patients after liver- or simultaneous liver and kidney transplantation

3. Having received a tacrolimus containing immunosuppressant therapeutic regimen at least for four weeks (induction therapy), and TL is within 5-20 ng/ml before inclusion

4. Patients signed an informed consent form for use of their pseudonymised clinical data within the present non-interventional trial.

Exclusion Criteria:

1. Participation in any clinical trial, 30 days prior to inclusion

2. The patients received liver allograft more than 6 months before inclusion

3. Hospitalisation due to infection, acute rejection, or graft disfunction 2 weeks prior to enrolment

4. Chronic graft insufficiency in the patient's history

5. Use of medications 2 weeks prior to enrolment, or the need for continuous use of medications that are known to significantly affect the pharmacokinetics of tacrolimus containing medications (as CYP3A4 inducers: rifampin, carbamazepine, phenobarbital, and phenytoin, or CYP3A4 inhibitors: erythromycin, ketoconazole, clarithromycin, and verapamil containing medication)

6. Presence of the following comorbidities:

1. Diseases affecting adherence to therapy (Chronic neurologic conditions, Psychiatric diseases)

2. Diseases affecting drug absorption and metabolism (Inflammatory bowel disease, Chronic inflammatory diseases of bile ducts, Presence of ascites due to any disease)

7. Patients on waiting list for re-transplantation

Related Conditions & MeSH terms

• Liver Failure

Intervention

Drug:
• Tacrolimus
Tacrolimus received as part of routine clinical care

Locations

Country	Name	City	State
Hungary	Semmelweis University, Department of Surgery, Transplantation and Gastroenterology	Budapest
Slovenia	University Medical Center Ljubljana, Division of Internal Medicine, Department of Gastroenterology	Ljubljana

Sponsors (2)

Lead Sponsor	Collaborator
Chiesi Hungary Ltd.	Chiesi Slovenija, d.o.o.

Countries where clinical trial is conducted

Hungary,  Slovenia, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Pharmacokinetic profile TL	To compare the trough level (TL) of different tacrolimus containing medications to Envarsus at each visit	12 months
Primary	Pharmacokinetic profile TDD	To compare the total daily dose (TDD) of different tacrolimus containing medications to Envarsus at each visit	12 months
Primary	Pharmacokinetic profile C/D	To compare the ration of TL and TDD (C/D) of different tacrolimus containing medications to Envarsus at each visit	12 months
Secondary	Liver function GGT	Changes in Gamma glutamine transferase (GGT) levels compared to baseline.	12 months
Secondary	Liver function AP	Changes in Alcalic phosphatase (AP) levels compared to baseline.	12 months
Secondary	Liver function GOT	Changes in Glutamyl oxaloacetic transaminase (GOT) levels compared to baseline.	12 months
Secondary	Liver function GPT	Changes in Glutamyl pyruvic transaminase (GPT) levels compared to baseline.	12 months
Secondary	Renal function	Change in the estimated glomerular filtration rate (eGFR) compared to baseline.	12 months
Secondary	Kinetics and function	To assess the possible relation of liver function parameters and eGFR to C/D (blood concentration and daily dosage)	12 months
Secondary	Rejection	Incidence of acute graft rejection during the study	12 months
Secondary	Virus infection	Incidence of BK and cytomegalovirus (CMV) infection during the study	12 months
Secondary	Variability	To assess the intraindividual variability of the TL, TDD and the ratios of these parameters (C/D)	12 months
Secondary	Adherence BAASIS	To assess the patient-adherence of therapy based on the BAASIS questionnaire	12 months
Secondary	Adherence prescriptions	To assess the patient-adherence of therapy based on the prescription filled by individual patients, based on electronic health-care record.	12 months